Aethlon Medical, Inc. (OTCBB:AEMD) today reported new data related to the safe use of the Hemopurifier(TM) treatment technology in animal studies. Researchers documented that the Hemopurifier, which has been developed to treat individuals infected with HIV (the AIDS virus), Hepatitis-C (HCV), and bioweapon threats, including Smallpox, was able to treat for extended periods of time without any adverse events. Aethlon has previously published pre-clinical data related to the rapid clearance of HIV, HCV and Smallpox related viruses from human blood. Aethlon Chairman & CEO James A. Joyce stated, “The demonstration of safety in animals combined with our known ability to capture infectious agents from human blood provides further clarity to our vision of treating humans in a safe and effective manner.”
